Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 7, 2009, Pages 2348-2352

  Roger, Thierry ^a   Froidevaux, Céline ^a   Le Roy, Didier ^a   Reymond, Marlies Knaup ^a   Chanson, Anne Laure ^a   Mauri, Davide ^b   Burns, Kim ^c   Riederer, Beat Michel ^c   Akira, Shizuo ^d   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Apotech Corporation   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Endotoxic shock; Gram negative bacteria; Lipopolysaccharide; TLR4

Indexed keywords

AMINO ACID DERIVATIVE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SEPTIC SHOCK;

ANIMALS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MODELS, GENETIC; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT FUSION PROTEINS; SEPSIS; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; NEGIBACTERIA;

EID: 60549101332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0808146106     Document Type: Article

References (38)

1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554.
2. Russell JA (2006) Management of sepsis. N Engl J Med 355:1699-1713.
3. Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: The story of endotoxin. Nat Rev Immunol 3:169-176.
4. Hoshino KO, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162:3749-3752.
5. Poltorak A, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088.
6. Qureshi ST, et al. (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189:615-625.
7. Schumann RR, et al. (1990) Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431.
8. Shimazu R, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189:1777-1782.
9. Tobias PS, Soldau K, Ulevitch RJ (1986) Isolation of a lipopolysaccharide-binding acute-phase reactant from rabbit serum. J Exp Med 164:777-793.
10. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS-binding protein. Science 249:1431-1433.
11. Kim JI, et al. (2005) Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 280:11347-11351.
12. Kim HM, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917.
13. Ohto U, Fukase K, Miyake K, Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316:1632-1634.
14. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19:24-32.
15. Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63-78.
16. Takeuchi O, Hoshino K, Akira S (2000) Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165:5392-5396.
17. Takeuchi O, et al. (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451.
18. Brodsky I, Medzhitov R (2007) Two modes of ligand recognition by TLRs. Cell 130:979-981.
19. Brandtzaeg P, Ovsteboo R, Kierulf P (1992) Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 166:650-652.
20. Nagai Y, et al. (2002) Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672.
21. Frevert CW, et al. (2000) Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 164:5439-5445.
22. Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP (1993) Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci U S A 90:9935-9938.
23. Le Roy D, et al. (2001) Critical role of lipopolysaccharide- binding protein and CD14 in immune responses against gram-negative bacteria. J Immunol 167:2759-2765.
24. Levin M, et al. (2000) Recombinant bactericidal/permeability- increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356:961-967.
25. Nadel S, et al. (2007) Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 369:836-843.
26. Daubeuf B, et al. (2007) TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 179:6107-6114.
27. Spiller S, et al. (2008) TLR4-induced IFN-{gamma} production increases TLR2 sensitivity and drives gram-negative sepsis in mice. J Exp Med 205:1747-1754.
28. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801.
29. Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J (2007) Contribution of Toll-like receptors tothe innate immune response to gram-negative and gram-positive bacteria. Blood 109:1574-1583.
30. Werts C, et al. (2001) Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2:346-352.
31. Lynn M, et al. (2003) Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187:631-639.
32. Mullarkey M, et al. (2003) Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304:1093-1102.
33. Solomon SB, et al. (2006) Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 193:634-644.
34. Marshall JC (2008) Sepsis: Rethinking the approach to clinical research. J Leukoc Biol 83:471-482.
35. Adachi O, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143-150.
36. Roger T, Ding X, Chanson AL, Renner P, Calandra T (2007) Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. Eur J Immunol 37:3509-3521.
37. Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414:920-924.
38. Roger T, Chanson AL, Knaup-Reymond M, Calandra T (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 35:3405-3413.